Insulet (PODD) Stock Price Today: $146.51 – Omnipod Maker Drops 6%
1 extracted signal · 0 resolved · 1 still active
Global News DailyIndependent analyst profile- Source published
- 09 Nov 2026, 10:40 UTC
- Recorded by Tahlil Plus
- 09 Nov 2026, 12:35 UTC

AI-generated source summary
Insulet Corporation (PODD) recently experienced a post-earnings sell-off despite beating estimates by 40 cents and announcing a massive $1 billion share repurchase program. Trading at a current price of $146.51, the stock reflects a severe valuation compression down to a 23.9x P/E multiple, driven primarily by long-term hedge fund de-grossing and lingering GLP-1 market fears. However, fundamentals remain remarkably robust with 19.2% revenue growth, expanding gross margins at 68.8%, and an industry-leading 85% customer retention rate via its core pharmacy subscription model. Key technical support levels sit at $143.50 and $126.40, while resistance is established at $165.00 and $185.00. With a 14-day RSI of 35.1 signaling oversold conditions, our base case 12-month target price is $185.00, with bull targets reaching $225.00 as the $400 million immediate Q4 buyback reduces float and operational leverage takes effect.
AI-generated summary based on the source content.
Signal outcomes at a glance
Tracking LiveSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
- Source processing completed
Source analysis and structured extraction completed.
- Live evaluation in progress
1 signal remains active.
Global News Daily
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.
